Skip to main content
Figure 1 | Trials

Figure 1

From: Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial

Figure 1

Study timeline. 120 subjects will undergo baseline investigations before entering a 4 week open-label run-in phase in which all subjects will receive 1600 mg of sevelamer carbonate with meals. Participants will then be randomised to continue treatment with sevelamer carbonate 1600 mg with meals or identical placebo for the remaining 36 weeks. Safety monitoring will be performed every four weeks. Investigations will be repeated at week 40 after which subjects will have completed participation in the study.

Back to article page

Trials

ISSN: 1745-6215